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Neurodegenerative disease is a widespread and growing burden with no disease-modifying treatment option. As 
we gain more knowledge on the source of neurotoxicity, monoclonal antibody-based drugs are actively being 
pursued as a treatment for neurodegeneration. Moreover, antibodies for detecting trace amounts of biomarker 
proteins in the cerebrospinal fluid and blood have shown promise in early detection and monitoring of 
neurodegeneration. However, as evidenced by recent failures in clinical trials of amyloid  targeting antibodies, 
development of a translatable drug for neurodegeneration is extremely challenging. A major hurdle to overcome 
is the validation and improvement of specificity towards targets that play a causal role in neurotoxicity. In this 
regard, the microtubule-associated protein tau and its 
disease-specific post-translational modification (PTM) sites 
have emerged as a promising target. Disease-specific PTMs 
appear prior to and drive the formation of tau oligomers, 
which have been identified as a key source of toxicity. A 
major clinical trial is underway with a tau monoclonal 
antibody targeting phosphorylated tau. However, efforts to 
validate the specificity of these antibodies has been scarce. 
An alarming and widespread lack of specificity in PTM-
targeting antibodies has only recently been noticed. More 
importantly, we have lacked the capability to improve 
antibody specificity even when the source of non-specific 
binding has been uncovered. This presentation will address 
our recent efforts to meet this urgent need by applying 
protein engineering approaches to identify high specificity 
antibodies targeting disease-specific PTM sites in the tau 
protein. Starting from a structure-based understanding of 
specificity in PTM-specific antibodies, I will describe our 
recent work on developing a quantitative parameter for 
measuring antibody specificity, in vitro directed evolution 
strategies to identify high specificity antibody variants, and 
new antibody library screening strategies to discover PTM-
specific antibodies. We find that antibody screening 
approaches that focus solely on affinity improvements likely 
result in antibody clones that have cross-reactivity towards 
the non-phosphorylated target. Multi-parameter screens 
that can measure specificity and affinity were essential in obtaining high quality antibodies that greatly improved 
phospho-tau detection in human patient samples [1]. These antibodies are invaluable tools for early detection of 
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Figure 1. Phospho-specific antibody 
binding. The interaction is mediated 
primarily by recognition of the phosphate 
group (solid box) and the target amino acid 
sequence (dotted box). Based on Protein 
Data Bank structure 4GLR. 
